Biogen Idec Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
316.63 1.57   0.50%128,7782.2M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

As of 10:10 AM ET 10/30/2014

Latest News Headlines for Biogen Idec Inc

Quarterly Earnings Releases, Technical Updates, Software Launches, Welfare Initiatives, and New Health Plans - Research Reports on Biogen, Express Scripts, Covidien, Alexion and Aetna

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, October 30, 2014 /PRNewswire/ -- Today, Analysts Review released its research reports regarding Biogen Idec Inc. (NASDAQ: BIIB), Express Scripts Holding Company (NASDAQ: ESRX), Covidien plc (NYSE: COV), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Aetna Inc. (NYSE: AET). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7558-100free.

Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin

Editor Note: For more information about this release, please scroll to bottom. LONDON, October 29, 2014 /PRNewswire/ -- Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), and Amarin Corporation PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 28, 2014, the NASDAQ Composite ended at 4,564.29, up 1.75%, the Dow Jones Industrial Average advanced 1.12%, to finish the day at 17,005.75, and the S&P 500 closed at 1,985.05, up 1.19%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index also advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:

Leading Researchers Join Biogen Idec to Advance Drug Discovery for Neurodegenerative Diseases

-- Christopher Henderson and Richard Ransohoff to Lead and Enhance the Company's Neurology Research and Discovery Effort -- CAMBRIDGE, Mass.--(BUSINESS WIRE)--October 23, 2014-- Biogen Idec (NASDAQ: BIIB) today announced that two leading neuroscientists have joined the company to advance its research in neurodegenerative diseases. Christopher Henderson, Ph.D., joins as vice president, Neurology. Richard Ransohoff, M.D., joins as senior research fellow, Neuroimmunology. The addition of these top researchers bolsters Biogen Idec's discovery engine.

View more recent headlines

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company's products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

http://www.biogenidec.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open315.09
Previous Close315.06
Day High318.00
Day Low313.91
52 Week High3/19/2014 | 358.89
52 Week Low11/8/2013 | 230.25
% Off 52 Week High-11.78%
% Off 52 Week Low37.52%
Beta (5 Yr)1.17
Volatility Avg10/29/2014 | 36.84
10-Day Avg. Volume2,208,792
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)9/30/2014 | 10.57
P/E Ratio9/30/2014 | 29.8
Market CapLarge Cap | 74.8B
Shares Outstanding236.16M
Float235.9M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short3.06M
Short Ratio2.2
Short % of Float1.30%
As of 10/15/2014

Peers Information HelpBIIB Biogen Idec Inc vs. Peers

Peers 
BIIB
Biogen Idec Inc
12.69%
Johnson & Johnson
15.25%
Pfizer Inc.
-3.72%
Merck & Co., Inc.
12.29%
AbbVie Inc
13.58%
BIIB
Biogen Idec Inc
0.00%
Johnson & Johnson
2.65%
Pfizer Inc.
3.53%
Merck & Co., Inc.
3.13%
AbbVie Inc
3.27%
BIIB
Biogen Idec Inc
0.50%
Johnson & Johnson
-0.32%
Pfizer Inc.
0.36%
Merck & Co., Inc.
0.59%
AbbVie Inc
0.37%
Compare these stocks